| Sr.No. | Description | Presentated By | Download |
|---|---|---|---|
| 1 | Post-covid syndrome in individuals admitted to hospital with covid-19: retrospective cohort study. BMJ 2021;372:n693 | Dr. Aanchal Aggarwal | |
| 2 | Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. Lancet 2021; 397: 1637–45 | Dr. Navneet Arora | |
| 3 | Once-Weekly Semaglutide in Adults with Overweight.N Engl J Med 2021;384:989-1002 | Dr. Suman | |
| 4 | Treatment of Multisystem Inflammatory Syndrome in Children. N Engl J Med 2021;385:11-22 | Dr. Sayonee Das | |
| 5 | Effectiveness of Covid-19 Vaccines against the B.1.617.2(Delta) Variant.N Engl J Med 2021;385:585-94 | Dr. Pranjjal Sindhu | |
| 6 | Final Report of a Trial of Intensive versus Standard Blood-Pressure Control.N Engl J Med 2021;384:1921-30. | Dr. Karthik. A | |
| 7 | Second intravenous immunoglobulin dose in patients with Guillain-Barré syndrome with poor prognosis (SID-GBS):a double-blind, randomised, placebo-controlled trial Lancet Neurol 2021; 20: 275–83 | Dr. S. Sidharth | |
| 8 | Therapeutic Anticoagulation with Heparin in Critically Ill Patients with Covid-19. REMAP- CAP, ACTIV-4a, and ATTACC Investigators. N Engl J Med 2021; 385:777-789. | Dr. P. Sathish | |
| 9 | Early assessment of the clinical severity of the SARS-CoV-2 omicron variant in South Africa: a data linkage study. Lancet. Pub. online 19 Jan 2022 | Dr. Chandan Kumar Dash | |
| 10 | Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial Lancet 2021; 398: 2258–76 | Dr. Aishwarya Malode |
